行情

SYBX

SYBX

Synlogic
NASDAQ

实时行情|Nasdaq Last Sale

1.590
-0.060
-3.64%
已收盘, 16:00 04/02 EDT
开盘
1.670
昨收
1.650
最高
1.740
最低
1.580
成交量
25.71万
成交额
--
52周最高
10.01
52周最低
1.350
市值
5,127.88万
市盈率(TTM)
-0.9208
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SYBX价格均价为7.81,最高价位13.00,最低价为2.000。

EPS

SYBX 新闻

更多
  • 沪指周跌0.3% 原油暴涨抵消失业潮利空、隔夜美股收高
  • 新浪财经 · 2小时前
  • 瑞幸咖啡盘前反弹 现涨2.8%
  • 新浪财经 · 3小时前
  • 神州租车疑似回应暴跌:一路上有风雨 但我们保持前行
  • 新浪科技 · 3小时前
  • 特朗普推动减产之际 OPEC+将于下周一举行网络会议
  • 新浪财经 · 3小时前

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.80%

热门股票

代码
价格
涨跌幅

SYBX 简况

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
展开

微牛提供Synlogic Inc(NASDAQ-SYBX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SYBX股票新闻,以帮助您做出投资决策。